|
Published by: Espicom Healthcare Intelligence
Published: May. 31, 2007 - 104 Pages
Table of Contents
- Volume 1
- EXECUTIVE SUMMARY
- BREAST CANCER
- THE FACTS
- PATIENT STATISTICS
- PATIENT MODEL
- THE MARKET
- GLOBAL CANCER MARKET
- THE BREAST CANCER MARKET
- CURRENT TREATMENTS
- CHEMOTHERAPY
- TARGETED THERAPY
- RESEARCH & DEVELOPMENT OF BC DRUGS
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- COMPETITOR RATIO ANALYSIS - COMPANIES
- DISCONTINUATION OF DRUGS
- APPENDIX 1
- APPENDIX 2
- APPENDIX 3
- APPENDIX 4
- APPENDIX 5
- APPENDIX 6
- APPENDIX 7
- GLOSSARY
- BIBLIOGRAPHY
- WEBSITE REFERENCES
- ACRONYMS
- COLORECTAL CANCER
- THE FACTS
- GLOBAL CANCER MARKET
- THE CRC MARKET
- CURRENT TREATMENTS
- CHEMOTHERAPY
- IMMUNOTHERAPY
- RESEARCH & DEVELOPMENT OF CRC DRUGS
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- COMPETITOR RATIO ANALYSIS - COMPANIES
- DISCONTINUATION OF DRUGS
- APPENDIX 1
- APPENDIX 2
- APPENDIX 3
- APPENDIX 4
- APPENDIX 5
- APPENDIX 6
- GLOSSARY
- BIBLIOGRAPHY
- ACRONYMS
- Volume 2
- NON-SMALL CELL LUNG CANCER
- THE FACTS
- GLOBAL CANCER MARKET
- THE NSCLC MARKET
- RESEARCH & DEVELOPMENT OF NSCLC DRUGS
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- DISCONTINUATION OF NSCLC DRUGS
- APPENDIX 1
- APPENDIX 2
- APPENDIX 3
- APPENDIX 4
- APPENDIX 5
- APPENDIX 6
- BIBLIOGRAPHY
- GLOSSARY
- ACRONYMS
- PROSTATE CANCER
- THE FACTS
- GLOBAL CANCER MARKET
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- DISCONTINUATION OF DRUGS
- APPENDIX 1
- APPENDIX 2
- APPENDIX 3
- APPENDIX 4
- APPENDIX 5
- APPENDIX 6
- GLOSSARY
- REFERENCES
- ACRONYMS
- RENAL CELL CARCINOMA
- THE FACTS
- THE MARKET
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- DISCONTINUATION OF DRUGS
- APPENDIX 1
- APPENDIX 2
- APPENDIX 3
AbstractThe renal cell carcinoma market was estimated to be worth around US$1 billion in 2006, with a growth rate of 36% YoY. Find out more about market developments in this chapter of Cancer Drug Discoveries.
Key questions answered include:
- What are the reasons behind the expected increase in the patient population with RCC?
- What impact will the new oral agents have on a market currently dominated by injectables?
- Why is only 25% of the global RCC market in Europe?
- What are the prospects for GSK’s pazopanib and what revenue contribution might it make in 2012?
- What challenges must Novartis overcome with Proleukin and its new product everolimus if it is to maintain market presence?
- What factors are limiting Wilex’ Rencarex commercialisation?
Get Full Details About This Report >>
|
